Waller A R, Chasseaud L F, Taylor T, Darragh A, O'Kelly D A
Biopharm Drug Dispos. 1979 Oct-Dec;1(2):59-64. doi: 10.1002/bdd.2510010203.
After single oral doses of 20 mg of a suspension of dihydralazine sulphate to human subjects, the peak of mean plasma concentrations of dihydralazine of 47.0 ng ml-1 +/- 11.0 standard deviation (S.D.) (n = 7) was reached at 1 h. Mean concentrations declined biphasically with apparent half-lives of 0.57 and 4.96 h respectively. Dihydralazine was partly converted to hydralazine. The peak of mean plasma concentrations of the latter drug of 3.9 ng ml-1 +/- 1.7 S.D. (n = 7) occurred at 1-2 h after dosing with dihydralazine sulphate and declined to 1.5 ng ml-1 +/- 1.5 S.D. at 6 h. Of the seven subjects studied, three were classified as fast and four as slow acetylators. Mean clearances appeared to be slightly more rapid in fast acetylators (1.63 l min-1 +/- 0.32 S.D.) when compared to slow acetylators (1.31 l min-1 +/- 0.31 S.D.) but this difference and differences in plasma concentrations and in areas under the plasma drug concentration-time curves were not significant (p > 0.1).
给人体受试者单次口服20mg硫酸双肼屈嗪混悬液后，双肼屈嗪的平均血浆浓度在1小时达到峰值47.0ng/ml±11.0标准差（S.D.）（n = 7）。平均浓度呈双相下降，表观半衰期分别为0.57小时和4.96小时。双肼屈嗪部分转化为肼屈嗪。后者药物的平均血浆浓度峰值为3.9ng/ml±1.7 S.D.（n = 7），在给予硫酸双肼屈嗪后1 - 2小时出现，6小时时降至1.5ng/ml±1.5 S.D.。在研究的7名受试者中，3名被归类为快速乙酰化者，4名被归类为慢速乙酰化者。与慢速乙酰化者（1.31l/min±0.31 S.D.）相比，快速乙酰化者的平均清除率似乎稍快（1.63l/min±0.32 S.D.），但这种差异以及血浆浓度和血浆药物浓度 - 时间曲线下面积的差异均无统计学意义（p>0.1）。
